As Nektar Therapeutics (NKTR) Share Price Rose, Holder Primecap Management Company Has Trimmed Stake

October 13, 2018 - By Ellis Scott

Nektar Therapeutics (NASDAQ:NKTR) LogoInvestors sentiment decreased to 1.13 in 2018 Q2. Its down 0.30, from 1.43 in 2018Q1. It dropped, as 54 investors sold NKTR shares while 100 reduced holdings. 82 funds opened positions while 92 raised stakes. 157.21 million shares or 2.48% more from 153.40 million shares in 2018Q1 were reported. Voya Management Limited Liability Com holds 92,436 shares. Alliancebernstein LP accumulated 0.01% or 258,196 shares. Andra Ap owns 15,800 shares. Dekabank Deutsche Girozentrale holds 0.03% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 98,904 shares. Sectoral Asset Mgmt Incorporated stated it has 73,614 shares or 0.4% of all its holdings. Tower Research Cap Limited Com (Trc) reported 1,813 shares stake. 3,191 were accumulated by Hanseatic Mgmt Inc. Zeke Capital Advsrs invested in 7,503 shares or 0.03% of the stock. 94,693 were accumulated by Td Asset Management Incorporated. Eagle Asset Mgmt Inc holds 0.21% in Nektar Therapeutics (NASDAQ:NKTR) or 804,760 shares. Ajo Lp holds 0% or 11,603 shares in its portfolio. Clarivest Asset Lc owns 17,200 shares or 0.01% of their US portfolio. Toth Fin Advisory Corp accumulated 45 shares. 6,994 are owned by Gateway Investment Advisers Ltd Liability. Moreover, First Trust Lp has 0.08% invested in Nektar Therapeutics (NASDAQ:NKTR) for 749,124 shares.

Since April 16, 2018, it had 1 insider buy, and 24 insider sales for $39.19 million activity. Thomsen Jillian B. sold $1.41 million worth of stock. Another trade for 12,791 shares valued at $1.07 million was sold by ROBIN HOWARD W. The insider GREER R SCOTT sold $602,786. $412,030 worth of Nektar Therapeutics (NASDAQ:NKTR) shares were sold by Labrucherie Gil M. Lingnau Lutz also sold $512,820 worth of Nektar Therapeutics (NASDAQ:NKTR) on Thursday, September 20. The insider Doberstein Stephen K sold 3,435 shares worth $286,445.

Primecap Management Company decreased its stake in Nektar Therapeutics (NKTR) by 0.75% based on its latest 2018Q2 regulatory filing with the SEC. Primecap Management Company sold 158,973 shares as the company’s stock rose 17.51% with the market. The institutional investor held 20.90M shares of the major pharmaceuticals company at the end of 2018Q2, valued at $1.02 billion, down from 21.06 million at the end of the previous reported quarter. Primecap Management Company who had been investing in Nektar Therapeutics for a number of months, seems to be less bullish one the $8.44B market cap company. The stock increased 2.11% or $1.01 during the last trading session, reaching $48.91. About 1.85 million shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 187.03% since October 13, 2017 and is uptrending. It has outperformed by 171.41% the S&P500.

Primecap Management Company, which manages about $87.86 billion and $134.88B US Long portfolio, upped its stake in Trimble Inc (NASDAQ:TRMB) by 141,725 shares to 9.66 million shares, valued at $317.25M in 2018Q2, according to the filing. It also increased its holding in Xencor (NASDAQ:XNCR) by 91,300 shares in the quarter, for a total of 7.57M shares, and has risen its stake in Intel Corp (NASDAQ:INTC).

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on November, 6. They expect $-0.58 EPS, down 256.76 % or $0.95 from last year’s $0.37 per share. After $5.33 actual EPS reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts -110.88 % negative EPS growth.

More recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: Seekingalpha.com which released: “Pegging The Value Of NKTR-214 At Zero” on October 02, 2018. Also Nasdaq.com published the news titled: “Did Bristol-Myers Squibb Make a Huge Mistake With Nektar?” on October 02, 2018. Seekingalpha.com‘s news article titled: “Refuting Nektar’s Apparent Response To Our Initial Report” with publication date: October 04, 2018 was also an interesting one.

Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage

Among 6 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Nektar Therapeutics had 7 analyst reports since April 20, 2018 according to SRatingsIntel. The firm has “Neutral” rating by H.C. Wainwright given on Monday, June 11. The company was maintained on Friday, May 11 by Canaccord Genuity. The firm earned “Overweight” rating on Monday, June 4 by JP Morgan. Canaccord Genuity maintained the shares of NKTR in report on Tuesday, June 5 with “Buy” rating. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Cowen & Co on Monday, June 4.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>